C4 Therapeutics Presents Compelling Data on Cemsidomide
C4 Therapeutics, Inc. (C4T), a progressive biopharmaceutical company focused on targeted protein degradation, has revealed exciting insights from its Phase 1 clinical trial of cemsidomide for treating multiple myeloma (MM). This data will be shared in an oral presentation set for the International Myeloma Society (IMS) Annual Meeting.
Upcoming IMS Annual Meeting Presentation Details
The presentation, titled "Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455) with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma," highlights significant progress in cemsidomide's development. It is scheduled for September 20, 2025, at 11:10 AM ET, during the session focused on future therapeutic targets.
Location and Key Presenter
The presentation will occur at the Metro Toronto Convention Centre, with Dr. Binod Dhakal from the Medical College of Wisconsin leading the discussion. His expertise in hematology will add depth to the information provided, aiming to capture the attention of attendees eager to learn about innovative treatments in MM.
Phase 1 Trial Insights
C4T has successfully completed patient enrollment and dose escalation for the clinical trial, which continues to exhibit a favorable safety profile and encouraging response rates. Data presented at the IMS will encompass all evaluable patients across the various dose levels of cemsidomide combined with dexamethasone.
Webcast Highlights Post-Presentation
Following the IMS presentation, C4T will host a webcast on the same day at 3 PM ET. This online event aims to delve deeper into the data and discuss the company's future clinical development strategies. Interested participants can find further details on the company's website.
About C4 Therapeutics
C4 Therapeutics stands at the forefront of biopharmaceutical innovation, dedicated to enhancing patient lives through targeted therapies. Leveraging its proprietary TORPEDO platform, C4T designs advanced small-molecule medicines that tackle challenging diseases. Their approach harnesses the body’s natural systems to degrade harmful proteins, offering potential solutions to issues like drug resistance.
Exploring Cemsidomide
Cemsidomide is an investigational drug noted for its potential effectiveness in targeting IKZF1 and IKZF3 transcription factors, which play a significant role in the progression of MM and non-Hodgkin’s lymphomas. Clinical data suggests that it is well tolerated and shows promise in anti-myeloma activity.
Contact Information
For further inquiries, C4T encourages interested parties to reach out to:
Investors: Courtney Solberg, Associate Director, Investor Relations (CSolberg@c4therapeutics.com)
Media: Loraine Spreen, Senior Director, Corporate Communications & Patient Advocacy (LSpreen@c4therapeutics.com)
Frequently Asked Questions
What is C4 Therapeutics known for?
C4 Therapeutics specializes in advanced biopharmaceuticals, focusing on targeted protein degradation and innovative treatment solutions.
When will the IMS Annual Meeting presentation take place?
The presentation is scheduled for September 20, 2025, at 11:10 AM ET.
Who will present the data at the IMS Annual Meeting?
Dr. Binod Dhakal will be the key presenter, sharing insights from the trial data.
What is the main focus of the Phase 1 trial?
The trial focuses on the effectiveness and safety of cemsidomide in patients with relapsed/refractory multiple myeloma.
How can I access the webcast after the presentation?
The webcast will be available on the C4 Therapeutics website, allowing viewers to catch up on detailed insights offered during the event.
